Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI117156

Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay.

A P Hollander, T F Heathfield, C Webber, Y Iwata, R Bourne, C Rorabeck, and A R Poole

Joint Diseases Laboratory, Shriners Hospital for Crippled Children, Montreal, Quebec, Canada.

Find articles by Hollander, A. in: PubMed | Google Scholar

Joint Diseases Laboratory, Shriners Hospital for Crippled Children, Montreal, Quebec, Canada.

Find articles by Heathfield, T. in: PubMed | Google Scholar

Joint Diseases Laboratory, Shriners Hospital for Crippled Children, Montreal, Quebec, Canada.

Find articles by Webber, C. in: PubMed | Google Scholar

Joint Diseases Laboratory, Shriners Hospital for Crippled Children, Montreal, Quebec, Canada.

Find articles by Iwata, Y. in: PubMed | Google Scholar

Joint Diseases Laboratory, Shriners Hospital for Crippled Children, Montreal, Quebec, Canada.

Find articles by Bourne, R. in: PubMed | Google Scholar

Joint Diseases Laboratory, Shriners Hospital for Crippled Children, Montreal, Quebec, Canada.

Find articles by Rorabeck, C. in: PubMed | Google Scholar

Joint Diseases Laboratory, Shriners Hospital for Crippled Children, Montreal, Quebec, Canada.

Find articles by Poole, A. in: PubMed | Google Scholar

Published April 1, 1994 - More info

Published in Volume 93, Issue 4 on April 1, 1994
J Clin Invest. 1994;93(4):1722–1732. https://doi.org/10.1172/JCI117156.
© 1994 The American Society for Clinical Investigation
Published April 1, 1994 - Version history
View PDF
Abstract

A new immunoassay was developed to detect denaturation of type II collagen in osteoarthritis (OA). A peptide, alpha 1 (II)-CB11B, located in the CB11 peptide of type II collagen, was synthesized and used to produce a monoclonal antibody (COL2-3/4m) of the IgG1 (kappa) isotype. This reacts with a defined epitope in denatured but not native type II collagen and the alpha 3 chain of type XI collagen. The latter is present in very small amounts (about 1% wt/wt) in cartilage relative to the alpha 1 (II) chain. By using an enzyme-linked immunosorbent assay, type II collagen denaturation and total type II collagen content were determined. The epitope recognized by the antibody was resistant to cleavage by alpha-chymotrypsin and proteinase K which were used to extract alpha 1 (II)-CB11B from the denatured (alpha-chymotrypsin soluble) and residual native (proteinase K soluble) collagen alpha-chains, respectively, present in human femoral articular cartilage. Type II collagen content was significantly reduced from a mean (range) of 14% (9.2-20.8%) of wet weight in 8 normal cartilages to 10.3% (7.4-15.0%) in 16 OA cartilages. This decrease, which may result in part from an increased hydration, was accompanied by an increase in the percent denaturation of type II collagen in OA to 6.0% of total type II collagen compared with 1.1% in normal tissue. The percent denaturation was ordinarily greater in the more superficial zone than in the deep zone of OA cartilage.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1722
page 1722
icon of scanned page 1723
page 1723
icon of scanned page 1724
page 1724
icon of scanned page 1725
page 1725
icon of scanned page 1726
page 1726
icon of scanned page 1727
page 1727
icon of scanned page 1728
page 1728
icon of scanned page 1729
page 1729
icon of scanned page 1730
page 1730
icon of scanned page 1731
page 1731
icon of scanned page 1732
page 1732
Version history
  • Version 1 (April 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts